Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

span>.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

This press release contains forward-looking statements about Amylin, Lilly and Alkermes. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA in a timely manner or at all; the companies' response to the complete response letter may not satisfy the FDA; the FDA may request additional information prior to
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... and Line of Credit -, NES-ZIONA, Israel, ... a biopharmaceutical company applying its,patented technology to develop ... it has closed a $2 million,equity investment by ... into a,line of credit agreement that provides for ...
... Conference, SAN DIEGO, March 27 SGX Pharmaceuticals,(Nasdaq: ... the SGX523 clinical program., In January 2008, the ... SGX523 in patients with solid tumor cancers. The first,trial ... on a continuous,28-day cycle and the second trial has ...
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
Cached Biology Technology:Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 2Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 3Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 4Modigene Announces Closing of $12 Million Financing by Members of The Frost Group 5SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 2SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 3
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... could pose a more serious threat to marine life ... Exeter, published today (19 July) in the British Ecological ... tens of thousands of turtles from across the Pacific ... Focusing on fisheries in Peru, the study suggests ...
... a new in vivo screening system, Whitehead Institute researchers ... that is essential in estrogen receptor (ER)-negative breast cancer. ... this proteinphosphoglycerate dehydrogenase or PHGDHis suppressed in tumors and ... rate of cellular growth declines markedly. RELEVANCE: ...
... move across surfaces prior to forming multicellular bacterial biofilms. ... known as "twitching" motility, which is made possible by ... or TFP. "TFP act like Batman,s ... and of chemistry and biochemistry at the UCLA Henry ...
Cached Biology News:Study shows small-scale fisheries' impact on marine life 2Key metabolic pathway implicated in intractable form of breast cancer 2UCLA study shows bacteria use Batman-like grappling hooks to 'slingshot' on surfaces 2
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Biology Products: